The attendance at the first-of-its-kind Women’s Cardiometabolic Health and Wellness Masterclass is limited to just 200 seats. This fixed capacity is designed to facilitate the intimate and relaxing environment at the heart of this educational Masterclass concept. Because of the limited nature of this event, interested attendees are encouraged to register early to reserve their spot at Terranea.

Accreditation Information

CMHC Masterclass On Demand: Women’s Cardiometabolic Health and Wellness

The educational design of this activity addresses the needs of US-based based cardiologists, endocrinologists, primary care clinicians, obstetricians, pharmacists, physicians, nurse practitioners, physician assistants, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

After completing this activity, the participant should be better able to:

  • Recognize the symptoms and clinical presentation of acute and chronic cardiovascular diseases in women, including heart failure, valvular disease, and acute coronary syndromes.
  • List unique CVD risk factors in women across the age spectrum
  • Describe the risk of cardiometabolic disease in women due to PCOS and adverse pregnancy outcomes.
  • Outline the cardiometabolic safety of postmenopausal hormone therapy and contraception.
  • Select individualized approaches for the screening and co-management of cardiometabolic risk and women’s health, including PCOS, postmenopausal symptoms, contraception, osteoporosis, infertility, and long-term pregnancy adverse outcomes.



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this enduring activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The maximum number of hours awarded for this Continuing Nursing Education activity is 6 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.


PACE designates this continuing education activity for 6 contact hour(s) (0.6 CEUs) of the Accreditation Council for Pharmacy Education. 

Universal Activity Number – JA4008073-9999-23-013-H01-P Type of activity: Knowledge 

Information on planner and faculty disclosure will be made available after registration.

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


There is a registration fee for this activity (if you were a live attendee please refer to the below note). Registration can be found here. Once registration is complete, you will receive a confirmation email with an access code and link back to this course.

If you attended the 2022 Women’s Health Masterclass, please reach out to [email protected] and we will provide you with complimentary access code to this activity.

During the period January 12, 2023 through January 12, 2024, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation.  Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at [email protected]

For additional information about the accreditation of this activity, please visit

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.